Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →ML Fraud Detection Score: 86%
Machine learning model identifies prescribing patterns consistent with confirmed fraud cases. This is a statistical indicator, not an accusation.
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
9,242
Total Claims
$340K
Drug Cost
858
Beneficiaries
$397
Cost/Patient
Risk Score Breakdown 9/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
+225%
Opioid rate vs peers
8.4% vs 2.6% avg
-63%
Cost per patient vs peers
$397 vs $1,068 avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
ML fraud detection score of 86% indicates prescribing patterns with significant similarity to confirmed fraud cases. 17 out of 20 decision trees flagged this provider.
Opioid rate is 225% above Family Practice peers. This is a significant deviation that may reflect a specialized patient population or concerning prescribing patterns.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
8.4%
Opioid Rate
774
Opioid Claims
$22K
Opioid Cost
10.2%
Long-Acting Rate
Brand vs Generic
Brand: 823 claims · $174K
Generic: 8,316 claims · $164K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dabigatran Etexilate Mesylate | 90 | $18K |
| Empagliflozin | 33 | $17K |
| Fluticasone Propion/Salmeterol | 59 | $16K |
| Rivaroxaban | 20 | $16K |
| Tiotropium Bromide | 36 | $13K |
| Insulin Nph Hum/Reg Insulin Hm | 20 | $12K |
| Apixaban | 20 | $10K |
| Atorvastatin Calcium | 727 | $9,998 |
| Hydrocodone/Acetaminophen | 473 | $9,188 |
| Insulin Nph Human Isophane | 49 | $8,998 |
| Fentanyl | 39 | $7,699 |
| Ciclesonide | 33 | $7,474 |
| Ticagrelor | 15 | $7,295 |
| Potassium Chloride | 173 | $6,788 |
| Amlodipine Besylate | 466 | $5,782 |
Prescribing Profile
Patient Profile
74
Avg Age
51%
Female
1.25
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data